microdosing on glp 1 GLP-1 is popular, but there's little evidence it works Microdosing GLP-1 | AgelessRx

Additionally, insulin resistance, another common metabolic issue associated with obesity, impairs the body's ability to respond to insulin, leading to elevated blood glucose levels that promote fat accumulation and contribute to inflammation

Sources: FDA Reuters PBS NYT BioPharma Dive Polsinelli Evaluate MarketsandMarkets Eli Lilly Investor Relations Picture by @AgingRoy To view or add a comment, sign in US-based Arrowhead Pharmaceuticals has announced that the Australian Therapeutic Goods Administration (TGA) has approved Redemplo (plozasiran) HCP, a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate

Other reported symptoms Sources: Phase 3 TRIUMPH-4 trial and Phase 2 NEJM trial Dysesthesia, or a change in skin sensation, was a new finding in the Phase 3 trial

Transport of fatty acids and metabolites across the peroxisomal membrane

GII THIU

Some private prescribers offer it off-label for weight management, but the NHS wont prescribe it for that purpose